CFMS:NSD-Conformis, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 1.46

Change

-0.01 (-0.68)%

Market Cap

USD 0.27B

Volume

2.44M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

-3.64 (-0.58%)

USD49.50B 108.54 77.15
PODD Insulet Corporation

+5.66 (+2.12%)

USD18.28B 2,101.18 161.07
ABMD Abiomed, Inc

+1.84 (+0.57%)

USD14.60B 65.17 56.43
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.68 (+0.84%)

USD12.24B 61.16 31.63
TNDM Tandem Diabetes Care, Inc

+2.49 (+2.44%)

USD6.39B N/A N/A
SWAV ShockWave Medical, Inc

+7.69 (+4.52%)

USD6.11B N/A N/A
IART Integra LifeSciences Holdings ..

-0.39 (-0.55%)

USD6.02B 35.73 21.47
INMD InMode Ltd

+1.88 (+1.73%)

USD4.27B 49.55 42.31
LIVN LivaNova PLC

+3.91 (+4.77%)

USD4.01B 77.40 N/A

ETFs Containing CFMS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 121.21% 91% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 121.21% 91% A- 96% A
Trailing 12 Months  
Capital Gain 88.83% 71% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 88.83% 71% C- 80% B-
Trailing 5 Years  
Capital Gain -79.05% 20% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.05% 20% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -5.07% 19% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.07% 19% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 96.30% 30% F 17% F
Risk Adjusted Return -5.26% 20% F 18% F
Market Capitalization 0.27B 40% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.82 78% C+ 48% F
Price / Cash Flow Ratio -14.65 56% F 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -54.62% 40% F 27% F
Return on Invested Capital -69.55% 24% F 11% F
Return on Assets -15.44% 40% F 22% F
Debt to Equity Ratio 219.86% 11% F 8% F
Technical Ratios  
Short Ratio 1.63 76% C 64% D
Short Percent 2.72% 60% D- 54% F
Beta 1.27 49% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector